year 17, Issue 4 (July - August 2023)                   Iran J Med Microbiol 2023, 17(4): 379-386 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Alborzi E, Tavakoli A, Kiani S J, Ghorbani S, Javanmard D, Sabaei M, et al . Prevalence of Human Cytomegalovirus Infection in Iranian Prostate Cancer Patients. Iran J Med Microbiol 2023; 17 (4) :379-386
1- Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
2- Research Center of Pediatric Infectious Diseases, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran
3- Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran
4- Antimicrobial Resistance Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran
5- Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran ,
Abstract:   (1240 Views)

Background and Aim: Human cytomegalovirus (HCMV) has the potential for oncogenicity and has been associated with many malignancies, including prostate cancer. This study aimed to investigate the genomic prevalence of HCMV in prostate cancer tumors.
Materials and Methods: In this case-control study, 31 patients with prostate cancer were enrolled along with 31 patients with benign prostate cancer as the control group. The presence of the HCMV genome was assessed using real-time polymerase chain reaction (PCR). The nested-PCR test was also used to detect the UL55 virus gene. Purified PCR products were sequenced using the Sanger method by a commercial service provider (Pishgam Co.), and the results were analized using Chromase software.
Results: The overall mean (±SD) prostate-specific antigen (PSA) value was 9 (±7.8) ng/Ml in patients with different stages of prostate cancer, and 9 (±3) ng/Ml in the control group (P=0.09). The prevalence of HCMV DNA was 19.3% (n=6) in the case group, and 6.5% (n=2) in the control group (P=0.14). The highest prevalence was observed in stage IIA (33.3%), followed by stages III (25%), and IIB (12.5%) (P=0.016). There were close phylogenetic relationships between Iranian HCMV isolates and several reference genotypes – the closest genetic relationship was observed with the KR 534207 genotype.
Conclusion: The prevalence of HCMV in the prostate cancer group was markedly higher than that of the control group, although this difference was not significant. However, the higher prevalence of HCMV in prostate cancer patients compared to the control group is indicative of the possible role of HCMV in the development of prostate cancer.

Full-Text [PDF 1736 kb]   (315 Downloads) |   |   Full-Text (HTML)  (169 Views)  
Type of Study: Original Research Article | Subject: Medical Virology
Received: 2023/01/17 | Accepted: 2023/06/19 | ePublished: 2023/09/27

1. Demaria S, Pikarsky E, Karin M, Coussens LM, Chen Y-C, El-Omar EM, et al. Cancer and Inflammation: Promise for Biological Therapy. J Immunother. 2010;33(4):335-51. [DOI:10.1097/CJI.0b013e3181d32e74] [PMID] [PMCID]
2. Moghoofei M, Keshavarz M, Ghorbani S, Babaei F, Nahand JS, Tavakoli A, et al. Association between human papillomavirus infection and prostate cancer: A global systematic review and meta-analysis. Asia Pac J Clin Oncol. 2019;15(5):e59-67. [DOI:10.1111/ajco.13124] [PMID]
3. Farahmand M, Monavari SH, Shoja Z, Ghaffari H, Tavakoli M, Tavakoli A. Epstein-Barr virus and risk of breast cancer: a systematic review and meta-analysis. Future Oncol. 2019;15(24):2873-85. [DOI:10.2217/fon-2019-0232] [PMID]
4. Salehi-Vaziri M, Sadeghi F, Bokharaei-Salim F, Younesi S, Alinaghi S, Monavari SH, et al. The Prevalence and Genotype Distribution of Human Papillomavirus in the Genital Tract of Males in Iran. Jundishapur J Microbio. 2015;8(12):e21912. [DOI:10.5812/jjm.21912]
5. Fateh A, Aghasadeghi M, Siadat SD, Vaziri F, Sadeghi F, Fateh R, et al. Comparison of Three Different Methods for Detection of IL28 rs12979860 Polymorphisms as a Predictor of Treatment Outcome in Patients with Hepatitis C Virus. Osong Public Health Res Perspect. 2016;7(2):83-9. [DOI:10.1016/j.phrp.2015.11.004] [PMID] [PMCID]
6. Sadeghi F, Bokharaei‐Salim F, Salehi‐Vaziri M, Monavari SH, Alavian SM, Salimi S, et al. Associations between human TRIM22 gene expression and the response to combination therapy with Peg-IFNα-2a and ribavirin in Iranian patients with chronic hepatitis C. J Med Virol. 2014;86(9):1499-506. [DOI:10.1002/jmv.23985] [PMID]
7. Salehi-Vaziri M, Sadeghi F, Alamsi-Hashiani A, Haeri H, Monavari SH, Keyvani H. Merkel cell polyomavirus and human papillomavirus infections in cervical disease in Iranian women. Arch Virol. 2015;160(5):1181-7. [DOI:10.1007/s00705-015-2368-4] [PMID]
8. Sadeghi F, Salehi‐Vaziri M, Alizadeh A, Ghodsi SM, Bokharaei‐Salim F, Fateh A, et al. Detection of Merkel cell polyomavirus large T-antigen sequences in human central nervous system tumors. J Med Virol. 2015;87(7):1241-7. [DOI:10.1002/jmv.24178] [PMID]
9. Sadeghi F, Salehi-Vaziri M, Ghodsi SM, Alizadeh A, Bokharaei-Salim F, Saroukalaei ST, et al. Prevalence of JC polyomavirus large T antigen sequences among Iranian patients with central nervous system tumors. Arch Virol. 2015;160(1):61-8. [DOI:10.1007/s00705-014-2230-0] [PMID]
10. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30(7):1073-81. [DOI:10.1093/carcin/bgp127] [PMID]
11. Grivennikov SI, Greten FR, Karin M. Immunity, Inflammation, and Cancer. Cell. 2010;140(6):883-99. [DOI:10.1016/j.cell.2010.01.025] [PMID] [PMCID]
12. Yang YM, Kim SY, Seki E, editors. Inflammation and liver cancer: molecular mechanisms and therapeutic targets. Seminars in liver disease; 2019: Thieme Medical Publishers. [DOI:10.1055/s-0038-1676806] [PMID] [PMCID]
13. Zhang J, Li X, Hu J, Cao P, Yan Q, Zhang S, et al. Long noncoding RNAs involvement in Epstein-Barr virus infection and tumorigenesis. Virology journal. 2020;17(1):1-8. [DOI:10.1016/j.virol.2019.12.012] [PMID] [PMCID]
14. Athanasiou E, Gargalionis AN, Boufidou F, Tsakris A. The Association of Human Herpesviruses with Malignant Brain Tumor Pathology and Therapy: Two Sides of a Coin. Int J Mol Sci. 2021;22(5):2250. [DOI:10.3390/ijms22052250] [PMID] [PMCID]
15. Tang K-W, Alaei-Mahabadi B, Samuelsson T, Lindh M, Larsson E. The landscape of viral expression and host gene fusion and adaptation in human cancer. Nat Commun. 2013;4(1):1-9. [DOI:10.1038/ncomms3513] [PMID] [PMCID]
16. Taher C, de Boniface J, Mohammad A-A, Religa P, Hartman J, Yaiw K-C, et al. High Prevalence of Human Cytomegalovirus Proteins and Nucleic Acids in Primary Breast Cancer and Metastatic Sentinel Lymph Nodes. PloS One. 2013;8(2):e56795. [DOI:10.1371/journal.pone.0056795] [PMID] [PMCID]
17. Poltermann S, Schlehofer B, Steindorf K, Schnitzler P, Geletneky K, Schlehofer J. Lack of association of herpesviruses with brain tumors. J Neurovirol. 2006;12(2):90-9. [DOI:10.1080/13550280600654573] [PMID]
18. Nauclér CS, Geisler J, Vetvik K. The emerging role of human cytomegalovirus infection in human carcinogenesis: a review of current evidence and potential therapeutic implications. Oncotarget. 2019;10(42):4333-47. [DOI:10.18632/oncotarget.27016] [PMID] [PMCID]
19. Fode M. Introduction for sexuality after prostate cancer. Int J Impot Res. 2021;33(4):389-90. [DOI:10.1038/s41443-020-00395-3] [PMID]
20. Auchus RJ, Sharifi N. Sex Hormones and Prostate Cancer. Annu Rev Med. 2020;71:33-45. [DOI:10.1146/annurev-med-051418-060357] [PMID]
21. Epstein JI, Allsbrook Jr WC, Amin MB, Egevad LL, Committee IG. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005;29(9):1228-42. [DOI:10.1097/01.pas.0000173646.99337.b1] [PMID]
22. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2016;40(2):244-52. [DOI:10.1097/PAS.0000000000000530] [PMID]
23. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;111(1):58-64. [DOI:10.1016/S0022-5347(17)59889-4] [PMID]
24. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017;67(2):93-9. [DOI:10.3322/caac.21388] [PMID]
25. Plotkin SA, Wang D, Oualim A, Diamond DJ, Kotton CN, Mossman S, et al. The Status of Vaccine Development Against the Human Cytomegalovirus. J Infect Dis. 2020;221(Supplement_1):S113-S22. [DOI:10.1093/infdis/jiz447] [PMID] [PMCID]
26. Archer M, Dogra N, Kyprianou N. Inflammation as a driver of prostate cancer metastasis and therapeutic resistance. Cancers. 2020;12(10):2984. [DOI:10.3390/cancers12102984] [PMID] [PMCID]
27. Bai B, Wang X, Chen E, Zhu H. Human cytomegalovirus infection and colorectal cancer risk: a meta-analysis. Oncotarget. 2016;7(47):76735-42. [DOI:10.18632/oncotarget.12523] [PMID] [PMCID]
28. Martinez-Fierro ML, Leach RJ, Gomez-Guerra LS, Garza-Guajardo R, Johnson-Pais T, Beuten J, et al. Identification of viral infections in the prostate and evaluation of their association with cancer. BMC Cancer. 2010;10(1):1-7. [DOI:10.1186/1471-2407-10-326] [PMID] [PMCID]
29. MEHRABANI KS, Ghane M, Ameli M. Prevalence of Cytomegalovirus Infection in Patients With Colorectal Cancer by Using PCR Technique. Zahedan j Res Med Sci. 2016;18(1):e5872.
30. Nakhaie M, Charostad J, Ghaderi-Zefrehi H, Arabzadeh SAM, Pourhosseini F, Makvandi M. Prevalence of Human Cytomegalovirus in Breast Cancer: A Systematic Review. Asian Pac J Cancer Prev. 2021;6(2):161-9. [DOI:10.31557/apjcb.2021.6.2.161-169]
31. Leiros GJ, Galliano SR, Sember ME, Kahn T, Schwarz E, Eiguchi K. Detection of human papillomavirus DNA and p53 codon 72 polymorphism in prostate carcinomas of patients from Argentina. BMC Urol. 2005;5(1):1-7. [DOI:10.1186/1471-2490-5-15] [PMID] [PMCID]
32. Sutcliffe S, Till C, Gaydos CA, Jenkins FJ, Goodman PJ, Hoque AM, et al. Prospective study of cytomegalovirus serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial. Cancer Causes Control. 2012;23(9):1511-8. [DOI:10.1007/s10552-012-0028-5] [PMID] [PMCID]
33. Zambrano A, Kalantari M, Simoneau A, Jensen JL, Villarreal LP. Detection of human polyomaviruses and papillomaviruses in prostatic tissue reveals the prostate as a habitat for multiple viral infections. Prostate. 2002;53(4):263-76. [DOI:10.1002/pros.10157] [PMID]
34. Bergh J, Marklund I, Gustavsson C, Wiklund F, Grönberg H, Allard A, et al. No link between viral findings in the prostate and subsequent cancer development. Br J Cancer. 2007;96(1):137-9. [DOI:10.1038/sj.bjc.6603480] [PMID] [PMCID]
35. Sfanos KS, Sauvageot J, Fedor HL, Dick JD, De Marzo AM, Isaacs WB. A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms. Prostate. 2008;68(3):306-20. [DOI:10.1002/pros.20680] [PMID]
36. Li Y, Huang M, Zhang Y, Chen J, Xu H, Wang G, et al. Automated Gleason Grading and Gleason Pattern Region Segmentation Based on Deep Learning for Pathological Images of Prostate Cancer. IEEE Access. 2020;8:117714-25. [DOI:10.1109/ACCESS.2020.3005180]
37. Mun Y, Paik I, Shin S-J, Kwak T-Y, Chang H. Yet Another Automated Gleason Grading System (YAAGGS) by weakly supervised deep learning. NPJ Digit Med. 2021;4(1):1-9. [DOI:10.1038/s41746-021-00469-6] [PMID] [PMCID]
38. Wang B, Gu W, Wan F, Wei Y, Xiao W, Lu X, et al. Prognosis of the 8th TNM Staging System for Penile Cancer and Refinement of Prognostication by Incorporating High Risk Human Papillomavirus Status. J Urol. 2020;203(3):562-9. [DOI:10.1097/JU.0000000000000584] [PMID]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Iranian Journal of Medical Microbiology

Designed & Developed by : Yektaweb | Publisher: Farname Inc